Table 3.
Association Between Known CAD and Outcomes
| Outcome | Participants With Event, n (%), Incidence Rate Per 100 Person‐Years | Unadjusted HR (95% CI) P Value | Adjusted HR (95% CI) P Value | |
|---|---|---|---|---|
| Known CAD (n=1791) | No Known CAD (n=2247) | |||
| Model 1a | ||||
| ESRD |
293 (16.4%) 7.5/100 |
375 (16.7%) 7.3/100 |
1.03 (0.89–1.21) 0.66 |
1.20 (1.01–1.42) 0.04 |
| Death or ESRD |
634 (35.4%) 15.9/100 |
636 (28.3%) 12.1/100 |
1.32 (1.18–1.47) <0.001 |
1.15 (1.01–1.30) 0.03 |
| Model 2b | ||||
| All‐cause death |
444 (24.8%) 10.3/100 |
363 (16.2%) 6.4/100 |
1.61 (1.40–1.85) 0.001 |
1.02 (0.87–1.20) 0.78 |
| Noncardiovascular death |
143 (8.0%) 3.3/100 |
155 (6.9%) 2.7/100 |
1.21 (0.96–1.52) 0.10 |
0.77 (0.60–1.00) 0.046 |
| Cardiovascular death |
301 (16.8%) 7.0/100 |
208 (9.3%) 3.7/100 |
1.91 (1.60–2.28) <0.001 |
1.21 (0.99–1.48) 0.06 |
CAD indicates coronary artery disease; ESRD, end‐stage renal disease; HR, hazard ratio.
Model 1 covariates: age, sex, race, body mass index, insulin use, estimated glomerular filtration rate, blood urea nitrogen, log urine protein/creatinine ratio, albumin, history of stroke, history of peripheral artery disease, history of heart failure, arrhythmia, hemoglobin, log ferritin, C‐reactive protein, history of acute renal failure, duration of diabetes, systolic blood pressure, and treatment with darbepoetin (renal model,15 plus duration of type 2 diabetes mellitus, systolic blood pressure, and treatment with darbepoetin).
Model 2 covariates: age, race, sex, history of heart failure, log urine protein/creatinine ratio, C‐reactive protein, abnormal ECG, serum albumin, arrhythmia, hemoglobin A1c, reticulocytes, blood urea nitrogen, insulin use, cerebrovascular disease, loop diuretics, hemoglobin level, and treatment with darbepoetin (cardiovascular model).14